Abhimanyu Ghose
Expertise in
3
conditions

Dr. Abhimanyu Ghose

Hematology
3645 S Rome St, Ste 209, 
Gilbert, AZ 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
3
conditions
3645 S Rome St, Ste 209, 
Gilbert, AZ 

Overview

Abhimanyu Ghose is a Hematologist practicing medicine in Gilbert, Arizona.

Dr. Ghose is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Agranulocytosis, Pulmonary Embolism, and Gastric Lymphoma.

Dr. Ghose is board certified in Internal Medicine (Sub: Medical Oncology), Internal Medicine (Sub: Hematology), and Internal Medicine. He is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 5 clinical trials. Dr. Ghose is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in OH

Board Certifications

Internal Medicine (Sub: Medical Oncology)
Internal Medicine (Sub: Hematology)
Internal Medicine

Fellowships

University of Cincinnati Hospital

Hospital Affiliations

Dignity Health Mercy Gilbert Medical Center
Mercy Gilbert Medical Center
Banner Desert Medical Center
Honor Health John C. Lincoln Medical Center
Chandler Regional Medical Center

Languages Spoken

English
Bengali
Hindi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Arizona Center for Hematology and Oncology
3645 S Rome St, Ste 209, Gilbert, AZ 85297

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Unknown
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

14 Total Publications

Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States.
Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States.
Journal: Journal of gastrointestinal oncology
Published: January 13, 2017
Similar Doctors
Expertise in
31
conditions
Expertise in
31
conditions
Referral may be required

AZ - Cancer

5777 E Mayo Blvd, 
Phoenix, AZ 
 (28.5 miles away)
480-933-6836
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeanne Palmer is a Hematologist practicing medicine in Phoenix, Arizona. Dr. Palmer is highly rated in 31 conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Myeloproliferative Neoplasms (MPN), Polycythemia Vera, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
32
conditions
Dr. Allison C. Rosenthal
Hematology | Oncology
Expertise in
32
conditions
Dr. Allison C. Rosenthal
Hematology | Oncology
Referral may be required

AZ - Cancer

5777 E Mayo Blvd, 
Phoenix, AZ 
 (28.5 miles away)
480-933-6836
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Allison Rosenthal is a Hematologist and an Oncologist practicing medicine in Phoenix, Arizona. Dr. Rosenthal is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Mayo Clinic Hospital In Arizona

5777 E Mayo Blvd, 
Phoenix, AZ 
 (28.5 miles away)
480-342-2000
Languages Spoken:
English
See accepted insurances

Lisa Rimsza is a Hematologist practicing medicine in Phoenix, Arizona. Dr. Rimsza is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Abhimanyu Ghose

How do I make an appointment with Dr. Abhimanyu Ghose?

You can book an appointment with Dr. Abhimanyu Ghose by calling their office at 623-238-7370. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Abhimanyu Ghose a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Abhimanyu Ghose is classified as an Advanced expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Abhimanyu Ghose specialize in?

While Dr. Abhimanyu Ghose is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Agranulocytosis, and Pulmonary Embolism. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Abhimanyu Ghose participate in research or clinical trials?

Yes. Dr. Abhimanyu Ghose has published 14 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Abhimanyu Ghose's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Abhimanyu Ghose accept my insurance?

Dr. Abhimanyu Ghose accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 623-238-7370 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ghose's expertise for a condition
ConditionClose
      View All 54 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile